Arantza Campo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arantza Campo has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Juan Pablo de Torres
Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
6 shared publications - Javier J. Zulueta
Departamento de Neumología, Clínica Universidad de Navarra, Pamplona, España
4 shared publications Ana B. Alcaide
Pulmonary Medicine, Clinica Universidad de Navarra, Pamplona, Spain
3 shared publicationsAna Belén Alcaide
Pulmonary Department. Clínica Universidad de Navarra, Pamplona, Spain
3 shared publicationsCarmen Felgueroso
Pulmonary Department. Clínica Universidad de Navarra, Pamplona, Spain
3 shared publicationsGorka Bastarrika
Radiology Department. Clínica Universidad de Navarra, Pamplona (Navarra), Spain
3 shared publications
Latest Publications
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA706
Microbiological Diagnosis Using Bronchoscopy In Patients With Bronchiectasis: Comparison Between Techniques And Association With Patient Characteristics.
Accurate microbiological diagnosis in bronchiectasis allows optimisation of treatment and infection control. Bronchoscopy may be useful in selected cases. Aims: To assess the diagnostic yield of bronchoscopy and sample types (BAS and BAL), identify frequent pathogens, and examine patient characteristics associated with these pathogens. Methods: Retrospective analysis of microbiological results from 160 bronchoscopies performed in 80 patients over 10 years. Results: We analysed 160 bronchoscopies (144 BAS, 140 BAL) in 80 CT‑confirmed bronchiectasis patients. Most were female (77.5%), mean age 64.5±12.6 years, BMI 23±4.1 kg/m². Forty per cent were smokers or former smokers, and 39.7% had airflow-limitation. Bronchiectasis was multilobar in 86.3% and bilateral in 78.8%. Pathogens were identified in 83.3%, mainly Mycobacteria (27.5%), Haemophilus spp. (18.7%), Pseudomonas spp. (13.1%), Staphylococcus aureus (8.1%) and Nocardia spp. (7.5%). Aspergillus spp. were detected in 51 cases. BAL showed higher yield for fungi; 38 pathogens were positive in only one sample type. In multivariate analysis, lower BMI was associated with Mycobacteria (p=0.041); older age and higher BMI with Staphylococcus aureus (p=0.001, p=0.05); airflow limitation with Pseudomonas spp. (p=0.05); smoking status with Nocardia spp. (p=0.024); and younger age with Haemophilus spp. (p=0.05). Conclusions: Bronchoscopy achieved an 83.8% diagnostic yield, with a notable proportion of Mycobacteria. BAS and BAL provide complementary information; collection of both is advisable. Several patient characteristics correlate with specific pathogens, particularly lower BMI with Mycobacteria and older age with Staphylococcus aureus.
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA706
Microbiological Diagnosis Using Bronchoscopy In Patients With Bronchiectasis: Comparison Between Techniques And Association With Patient Characteristics.
Accurate microbiological diagnosis in bronchiectasis allows optimisation of treatment and infection control. Bronchoscopy may be useful in selected cases. Aims: To assess the diagnostic yield of bronchoscopy and sample types (BAS and BAL), identify frequent pathogens, and examine patient characteristics associated with these pathogens. Methods: Retrospective analysis of microbiological results from 160 bronchoscopies performed in 80 patients over 10 years. Results: We analysed 160 bronchoscopies (144 BAS, 140 BAL) in 80 CT‑confirmed bronchiectasis patients. Most were female (77.5%), mean age 64.5±12.6 years, BMI 23±4.1 kg/m². Forty per cent were smokers or former smokers, and 39.7% had airflow-limitation. Bronchiectasis was multilobar in 86.3% and bilateral in 78.8%. Pathogens were identified in 83.3%, mainly Mycobacteria (27.5%), Haemophilus spp. (18.7%), Pseudomonas spp. (13.1%), Staphylococcus aureus (8.1%) and Nocardia spp. (7.5%). Aspergillus spp. were detected in 51 cases. BAL showed higher yield for fungi; 38 pathogens were positive in only one sample type. In multivariate analysis, lower BMI was associated with Mycobacteria (p=0.041); older age and higher BMI with Staphylococcus aureus (p=0.001, p=0.05); airflow limitation with Pseudomonas spp. (p=0.05); smoking status with Nocardia spp. (p=0.024); and younger age with Haemophilus spp. (p=0.05). Conclusions: Bronchoscopy achieved an 83.8% diagnostic yield, with a notable proportion of Mycobacteria. BAS and BAL provide complementary information; collection of both is advisable. Several patient characteristics correlate with specific pathogens, particularly lower BMI with Mycobacteria and older age with Staphylococcus aureus.
- Open Access
- 8 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0320704
Exploring the impact of surgical treatment for lung cancer in patients with Airway Obstruction from a Lung Cancer Screening Program
Introduction: Little information is available on the surgical treatment options for patients with Airway Obstruction (AO) and early-stage non-small cell lung cancer (NSCLC) followed in lung cancer screening programs (LCS). This study aims to compare the potential impact of anatomical sub lobar resections vs. lobectomies in these patients. Methods: This is a retrospective analysis of participants who underwent surgical resections within a Lung Cancer Screening Program, including those with AO (post bronchodilator FEV1/FVC < 0.70). The short-term survival, locoregional recurrence, perioperative complications, and difference between pre and postoperative pulmonary function tests were compared between the surgical groups in those with AO. Results: Anatomical sub lobar resections or lobectomies for Stages IA and IB NSCLC were performed in 133 patients. Out of these, 57 had AO. Anatomical sub lobar resections were non-inferior to lobectomies for short-term survival in patients with AO (3-year survival rate: 95.8% vs. 97%, p = 0.83). In these patients, sub lobar resections had a higher recurrence rate (12.5% vs 0%, p < 0.01). No significant differences were found in postoperative complications between surgical techniques (sub lobar 33% vs lobectomy 24%, p = 0.44). Lastly, no significant difference was found on the change between pre and postoperative FEV1 and DLCO (p = 0.96 and 0.79 for FEV1 and DLCO, respectively). Conclusions: The present retrospective analysis suggests that sub lobar resection might be the best surgical option for treating early-stage NSCLC in patients with AO, where lung function preservation techniques are desired, but requires closer follow up to detect recurrence. Further studies in larger samples should confirm our findings.
- 8 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0320704
Open AccessExploring the impact of surgical treatment for lung cancer in patients with Airway Obstruction from a Lung Cancer Screening Program
Introduction: Little information is available on the surgical treatment options for patients with Airway Obstruction (AO) and early-stage non-small cell lung cancer (NSCLC) followed in lung cancer screening programs (LCS). This study aims to compare the potential impact of anatomical sub lobar resections vs. lobectomies in these patients. Methods: This is a retrospective analysis of participants who underwent surgical resections within a Lung Cancer Screening Program, including those with AO (post bronchodilator FEV1/FVC < 0.70). The short-term survival, locoregional recurrence, perioperative complications, and difference between pre and postoperative pulmonary function tests were compared between the surgical groups in those with AO. Results: Anatomical sub lobar resections or lobectomies for Stages IA and IB NSCLC were performed in 133 patients. Out of these, 57 had AO. Anatomical sub lobar resections were non-inferior to lobectomies for short-term survival in patients with AO (3-year survival rate: 95.8% vs. 97%, p = 0.83). In these patients, sub lobar resections had a higher recurrence rate (12.5% vs 0%, p < 0.01). No significant differences were found in postoperative complications between surgical techniques (sub lobar 33% vs lobectomy 24%, p = 0.44). Lastly, no significant difference was found on the change between pre and postoperative FEV1 and DLCO (p = 0.96 and 0.79 for FEV1 and DLCO, respectively). Conclusions: The present retrospective analysis suggests that sub lobar resection might be the best surgical option for treating early-stage NSCLC in patients with AO, where lung function preservation techniques are desired, but requires closer follow up to detect recurrence. Further studies in larger samples should confirm our findings.
- Open Access
- 19 November 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 236, 107861
Dietary patterns and asthma incidence in adult population. Systematic review and meta-analysis
- 19 November 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 236, 107861
Open AccessDietary patterns and asthma incidence in adult population. Systematic review and meta-analysis
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1110
Assessing lung cancer risk in young and elderly patients in a lung cancer screening programme
Lung cancer screening with low dose CT (LDCT) allows diagnosis of lung cancer in early stages as well as improved survival. The selection of patients at risk is crucial in order to optimize the resources and outcomes of the screening programs. Actual recommendations for screening include age (50 to 80 years-old) and smoking burden. Objective: To assess the risk for cancer and associated factors within a 20-year running program (P-iELCAP, Spain) specifically in patients with 80 years. Results: 4162 patients participated in the lung cancer programme from 2000 to 2022, with 17075 LDCTs performed. PFTs were performed in 2552 patients. At enrolment, 1864, 2265 and 33 patients were 80 years-old respectively. Frequency of cancer diagnosed at first round (prevalent) and compared to reference group (1.32%) was 0,21% (p<0,001), and 6.06% (p=0.079), respectively. During the whole period of study, there were 143 diagnoses of cancer in 124 patients: 13 in 80 years-old. The presence of emphysema on CT had significant risk for cancer in the whole group after adjusting for age and pack-years (OR 2.078; 95%CI 1.46 – 2.956; p<0.001), but emphysema had a particularly high OR for lung cancer of 14.79 (95%CI 3.45 - 63.7), p<0.001 in <55 years. A value of DLCO<90% adjusted for age and pack-years also had an OR of 1,847 (IC95% 1,022 – 3,338; p=0,042). Conclusions: Lung cancer risk is associated with age, smoking burden, and emphysema, this latter particularly in younger subjects. A DLCO<90% portends a higher risk for cancer and might be considered as a tool for assessing lung cancer risk before screening enrolment.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA1110
Assessing lung cancer risk in young and elderly patients in a lung cancer screening programme
Lung cancer screening with low dose CT (LDCT) allows diagnosis of lung cancer in early stages as well as improved survival. The selection of patients at risk is crucial in order to optimize the resources and outcomes of the screening programs. Actual recommendations for screening include age (50 to 80 years-old) and smoking burden. Objective: To assess the risk for cancer and associated factors within a 20-year running program (P-iELCAP, Spain) specifically in patients with 80 years. Results: 4162 patients participated in the lung cancer programme from 2000 to 2022, with 17075 LDCTs performed. PFTs were performed in 2552 patients. At enrolment, 1864, 2265 and 33 patients were 80 years-old respectively. Frequency of cancer diagnosed at first round (prevalent) and compared to reference group (1.32%) was 0,21% (p<0,001), and 6.06% (p=0.079), respectively. During the whole period of study, there were 143 diagnoses of cancer in 124 patients: 13 in 80 years-old. The presence of emphysema on CT had significant risk for cancer in the whole group after adjusting for age and pack-years (OR 2.078; 95%CI 1.46 – 2.956; p<0.001), but emphysema had a particularly high OR for lung cancer of 14.79 (95%CI 3.45 - 63.7), p<0.001 in <55 years. A value of DLCO<90% adjusted for age and pack-years also had an OR of 1,847 (IC95% 1,022 – 3,338; p=0,042). Conclusions: Lung cancer risk is associated with age, smoking burden, and emphysema, this latter particularly in younger subjects. A DLCO<90% portends a higher risk for cancer and might be considered as a tool for assessing lung cancer risk before screening enrolment.
- 20 March 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (10) , 1100-1108
Lung cancer screening using low-dose CT and FDG-PET in liver transplant recipients
To address the feasibility of implementing a lung cancer screening program in liver transplant recipients (LTR) targeted to detect early-stage lung cancer one hundred twenty-four LTR (89% male, 59.8+/−8.8 y old), who entered the lung cancer screening program at our hospital were reviewed. The results of the diagnostic algorithm using low-dose CT and F-18-fluorodeoxyglycose positron emission tomography (FDG-PET) were analyzed. Lung cancer was detected in 12 LTR (9.7%), most of which corresponded to the non-small cell subtype. Two of the 12 lung cancers were detected in the baseline study (prevalence of 1.6%), whereas 10 patients were diagnosed with lung cancer in the follow-up (incidence of 8.1%). Considering all cancers, 10 of 12 (83.3%) were diagnosed at stage I, one cancer was diagnosed at stage IIIA, and another one at stage IV. The sensitivity, specificity, diagnostic accuracy, and positive and negative predictive values of F-18-fluorodeoxyglycose positron emission tomography to detect malignancy in our cohort were 81.8%,100%, 99.3%, 100%, and 99.3%, respectively. A carefully followed multidisciplinary lung cancer screening algorithm in LTR that includes F-18-fluorodeoxyglycose positron emission tomography and low-dose CT allows lung cancer to be diagnosed at an early stage while reducing unnecessary invasive procedures.
- 20 March 2023
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 29 (10) , 1100-1108
Lung cancer screening using low-dose CT and FDG-PET in liver transplant recipients
To address the feasibility of implementing a lung cancer screening program in liver transplant recipients (LTR) targeted to detect early-stage lung cancer one hundred twenty-four LTR (89% male, 59.8+/−8.8 y old), who entered the lung cancer screening program at our hospital were reviewed. The results of the diagnostic algorithm using low-dose CT and F-18-fluorodeoxyglycose positron emission tomography (FDG-PET) were analyzed. Lung cancer was detected in 12 LTR (9.7%), most of which corresponded to the non-small cell subtype. Two of the 12 lung cancers were detected in the baseline study (prevalence of 1.6%), whereas 10 patients were diagnosed with lung cancer in the follow-up (incidence of 8.1%). Considering all cancers, 10 of 12 (83.3%) were diagnosed at stage I, one cancer was diagnosed at stage IIIA, and another one at stage IV. The sensitivity, specificity, diagnostic accuracy, and positive and negative predictive values of F-18-fluorodeoxyglycose positron emission tomography to detect malignancy in our cohort were 81.8%,100%, 99.3%, 100%, and 99.3%, respectively. A carefully followed multidisciplinary lung cancer screening algorithm in LTR that includes F-18-fluorodeoxyglycose positron emission tomography and low-dose CT allows lung cancer to be diagnosed at an early stage while reducing unnecessary invasive procedures.
- 17 October 2022
- Published by American Speech Language Hearing Association in Journal of Speech, Language, and Hearing Research
- Vol. 65 (10) , 3789-3797
Describing the Acoustic and Vocal Production Characteristics of the Irrintzi: Feasibility of Its Use for the Treatment of Voice Disorders
Purpose: The aims of this study were to analyze and characterize the irrintzi (a folkloric shout emitted in a single breath used by the Basque people) acoustically and to describe the mechanism by which it is emitted. Method: Thirty-six sound samples of 12 female volunteers were analyzed. Acoustic analysis included primarily fundamental frequency ( f o ), spectral analysis in the time domain with a narrowband filter, and the use of linear predictive coding (LPC). Laryngeal and pharyngeal movements while emitting an irrintzi were studied by fiberoptic nasal endoscopy. Postural and mandible movements were observed and video recorded. Movements of the larynx and the vocal tract were also studied by lateral pharyngo-laryngeal radioscopy. Results: The central part of an irrintzi spectrogram contains a peculiar, repeated M-shaped motif unseen in the spectrogram of any other human vocal emission, and intensity was over 90 dB SPL in all cases. f o was very high (1487 Hz) especially at the end of the irrintzi. Fiberoptic nasal endoscopy consistently revealed considerable elevation of the glottis, with the larynx swinging forward and retraction of the ventricular bands. Lateral radioscopy showed a very high larynx and a high tongue dorsum. Conclusions: The irrintzi is a sound emitted in a single breath and characterized by its shrillness and loudness, qualities that make it audible in noisy environments and over large distances and the vocal technique observed when it is produced can be explained by the Estill voice model (Steinhauer et al., 2017). The use of this technique may help in the treatment of voice disorders and improve efficiency in singers, teachers, actors, and people who use their voice at high volume or at high frequency. Supplemental Material: https://doi.org/10.23641/asha.20779405
- 17 October 2022
- Published by American Speech Language Hearing Association in Journal of Speech, Language, and Hearing Research
- Vol. 65 (10) , 3789-3797
Describing the Acoustic and Vocal Production Characteristics of the Irrintzi: Feasibility of Its Use for the Treatment of Voice Disorders
Purpose: The aims of this study were to analyze and characterize the irrintzi (a folkloric shout emitted in a single breath used by the Basque people) acoustically and to describe the mechanism by which it is emitted. Method: Thirty-six sound samples of 12 female volunteers were analyzed. Acoustic analysis included primarily fundamental frequency ( f o ), spectral analysis in the time domain with a narrowband filter, and the use of linear predictive coding (LPC). Laryngeal and pharyngeal movements while emitting an irrintzi were studied by fiberoptic nasal endoscopy. Postural and mandible movements were observed and video recorded. Movements of the larynx and the vocal tract were also studied by lateral pharyngo-laryngeal radioscopy. Results: The central part of an irrintzi spectrogram contains a peculiar, repeated M-shaped motif unseen in the spectrogram of any other human vocal emission, and intensity was over 90 dB SPL in all cases. f o was very high (1487 Hz) especially at the end of the irrintzi. Fiberoptic nasal endoscopy consistently revealed considerable elevation of the glottis, with the larynx swinging forward and retraction of the ventricular bands. Lateral radioscopy showed a very high larynx and a high tongue dorsum. Conclusions: The irrintzi is a sound emitted in a single breath and characterized by its shrillness and loudness, qualities that make it audible in noisy environments and over large distances and the vocal technique observed when it is produced can be explained by the Estill voice model (Steinhauer et al., 2017). The use of this technique may help in the treatment of voice disorders and improve efficiency in singers, teachers, actors, and people who use their voice at high volume or at high frequency. Supplemental Material: https://doi.org/10.23641/asha.20779405
- Open Access
- 29 April 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 7 (2)
Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases.Objectives: To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.Methods: A phase I multicentre clinical trial (ClinicalTrials.govNCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10×106, 50×106and 100×106cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months.Results: 21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months.Conclusions: The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous MSCs in IPF patients.
- 29 April 2021
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 7 (2)
Open AccessEndobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial
Rationale: Idiopathic pulmonary fibrosis (IPF) has a dismal prognosis. Mesenchymal stromal cells (MSCs) have shown benefit in other inflammatory diseases.Objectives: To evaluate the safety and feasibility of endobronchial administration of bone marrow autologous MSCs (BM-MSC) in patients with mild-to-moderate IPF.Methods: A phase I multicentre clinical trial (ClinicalTrials.govNCT01919827) with a single endobronchial administration of autologous adult BM-MSCs in patients diagnosed with mild-to-moderate IPF. In a first escalating-dose phase, three patients were included sequentially in three dose cohorts (10×106, 50×106and 100×106cells). In a second phase, nine patients received the highest tolerated dose. Follow-up with pulmonary function testing, 6-min walk test and St George's Respiratory Questionnaire was done at 1, 2, 3, 6 and 12 months, and with computed tomography at 3, 6 and 12 months.Results: 21 bone marrow samples were obtained from 17 patients. Three patients were excluded from treatment due to chromosome aberrations detected in MSCs after culture, and one patient died before treatment. Finally, 13 patients received the BM-MSC infusion. No treatment-related severe adverse events were observed during follow-up. Compared to baseline, the mean forced vital capacity showed an initial decline of 8.1% at 3 months. The number of patients without functional progression was six (46%) at 3 months and three (23%) at 12 months.Conclusions: The endobronchial infusion of BM-MSCs did not cause immediate serious adverse events in IPF patients, but a relevant proportion of patients suffered clinical and/or functional progression. Genomic instability of BM-MSCs during culture found in three patients may be troublesome for the use of autologous MSCs in IPF patients.
- Open Access
- 1 July 2020
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 1823-1829
Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD
Rationale: Emphysema and osteoporosis are tobacco-related diseases. Many studies have shown that emphysema is a strong and independent predictor of low bone mineral density (BMD) in smokers; however, none of them explored its association with different emphysema subtypes. Objective: To explore the association between the different emphysema subtypes and the presence of low bone mineral density in a population of active or former smokers with and without chronic obstructive pulmonary disease (COPD). Methods: One hundred and fifty-three active and former smokers from a pulmonary clinic completed clinical questionnaires, pulmonary function tests, a low-dose chest computed tomography (LDCT) and a dual-energy absorptiometry (DXA) scans. Subjects were classified as having normal BMD or low BMD (osteopenia or osteoporosis). Emphysema was classified visually for its subtype and severity. Logistic regression analysis explored the relationship between the different emphysema subtypes and the presence of low BMD adjusting for other important factors. Results: Seventy-five percent of the patients had low BMD (78 had osteopenia and 37 had osteoporosis). Emphysema was more frequent (66.1 vs 26.3%, p=< 0.001) and severe in those with low BMD. Multivariable analysis adjusting for other significant cofactors (age, sex, FEV1, and severity of emphysema) showed that BMI (OR=0.91, 95% CI: 0.76– 0.92) and centrilobular emphysema (OR=26.19, 95% CI: 1.71 to 399.44) were associated with low BMD. Conclusion: Low BMD is highly prevalent in current and former smokers. BMI and centrilobular emphysema are strong and independent predictors of its presence, which suggests that they should be considered when evaluating smokers at risk for low BMD.
- 1 July 2020
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 15, 1823-1829
Open AccessExploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD
Rationale: Emphysema and osteoporosis are tobacco-related diseases. Many studies have shown that emphysema is a strong and independent predictor of low bone mineral density (BMD) in smokers; however, none of them explored its association with different emphysema subtypes. Objective: To explore the association between the different emphysema subtypes and the presence of low bone mineral density in a population of active or former smokers with and without chronic obstructive pulmonary disease (COPD). Methods: One hundred and fifty-three active and former smokers from a pulmonary clinic completed clinical questionnaires, pulmonary function tests, a low-dose chest computed tomography (LDCT) and a dual-energy absorptiometry (DXA) scans. Subjects were classified as having normal BMD or low BMD (osteopenia or osteoporosis). Emphysema was classified visually for its subtype and severity. Logistic regression analysis explored the relationship between the different emphysema subtypes and the presence of low BMD adjusting for other important factors. Results: Seventy-five percent of the patients had low BMD (78 had osteopenia and 37 had osteoporosis). Emphysema was more frequent (66.1 vs 26.3%, p=< 0.001) and severe in those with low BMD. Multivariable analysis adjusting for other significant cofactors (age, sex, FEV1, and severity of emphysema) showed that BMI (OR=0.91, 95% CI: 0.76– 0.92) and centrilobular emphysema (OR=26.19, 95% CI: 1.71 to 399.44) were associated with low BMD. Conclusion: Low BMD is highly prevalent in current and former smokers. BMI and centrilobular emphysema are strong and independent predictors of its presence, which suggests that they should be considered when evaluating smokers at risk for low BMD.
- Open Access
- 13 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0231204
Prevalence and burden of bronchiectasis in a lung cancer screening program
The prevalence of bronchiectasis in the general population and in individuals undergoing lung cancer screening with low dose computed tomography (LDCT) is unknown. The aim of this study is to estimate the prevalence and impact of bronchiectasis in a screening lung cancer program. 3028 individuals participating in an international multicenter lung cancer screening consortium (I-ELCAP) were selected from 2000 to 2012. Patients with bronchiectasis on baseline CT were identified and compared to selected controls. Detection of nodules, need for additional studies and incidence of cancer were analyzed over the follow-up period. The prevalence of bronchiectasis was 11.6%(354/3028). On the baseline LDCT, the number of subjects with nodules identified was 189(53.4%) in patients with bronchiectasis compared to 63(17.8%) in controls (pvs. 88(12.17%) for controls (p = 0.008).The incidence rate of lung cancer during follow-up was 6.8/1000 and 5.1/1000 person-years for each group respectively (p = 0.62) Bronchiectasis are common among current and former smokers undergoing lung cancer screening with LDCT. The presence of bronchiectasis is associated with greater incidence of new nodules and false positives on baseline and follow-up screening rounds. This leads to an increase need of diagnostic tests, although the lung cancer occurrence is not different.
- 13 April 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (4) , e0231204
Open AccessPrevalence and burden of bronchiectasis in a lung cancer screening program
The prevalence of bronchiectasis in the general population and in individuals undergoing lung cancer screening with low dose computed tomography (LDCT) is unknown. The aim of this study is to estimate the prevalence and impact of bronchiectasis in a screening lung cancer program. 3028 individuals participating in an international multicenter lung cancer screening consortium (I-ELCAP) were selected from 2000 to 2012. Patients with bronchiectasis on baseline CT were identified and compared to selected controls. Detection of nodules, need for additional studies and incidence of cancer were analyzed over the follow-up period. The prevalence of bronchiectasis was 11.6%(354/3028). On the baseline LDCT, the number of subjects with nodules identified was 189(53.4%) in patients with bronchiectasis compared to 63(17.8%) in controls (pvs. 88(12.17%) for controls (p = 0.008).The incidence rate of lung cancer during follow-up was 6.8/1000 and 5.1/1000 person-years for each group respectively (p = 0.62) Bronchiectasis are common among current and former smokers undergoing lung cancer screening with LDCT. The presence of bronchiectasis is associated with greater incidence of new nodules and false positives on baseline and follow-up screening rounds. This leads to an increase need of diagnostic tests, although the lung cancer occurrence is not different.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA3026
Risk factors and prognosis of non-solid nodules in a lung cancer screening program
Objectives: To study the prevalence of non-solid lung nodules in patients undergoing lung cancer screening, analyze their prognosis during the follow-up and identify risk factors. Material and Methods: Investigations on non-solid lung nodules found on CT were revised. Medical records and database of the participants in a lung cancer screening program with low-dose chest CT (P-ELCAP (Pamplona – Early Lung Cancer Action Program) were analyzed. Tobacco, bronchiectasis, emphysema, age and sex data were compared between patients with and without non-solid nodules. The lung cancer frequency in both groups of patients was compared and the percentage of non-solid nodules that developed in cancer was determined. Results: We included 3624 patients. The prevalence of non-solid lung nodules was 7.51% and the prevalence of cancer among the patients was 2.24%. The progression into cancer from a non-solid nodule appear in 7 of 272 patients with non-solid nodules. In comparison with the rest of the patients, the group with non-solid lung nodules, its number of women was 94 (34.56%) vs. 927 (27.7%); p = 0.015 and the prevalence of lung cancer was 21 (7.72%) vs. 60 (1.79%) p <0.001. For the association of greater tobacco consumption, with the presence of non-solid nodules, adjusted for sex, an OR 1.01, 95% CI (1.00 - 1.01) p = 0.007 was obtained. The presence of non-solid nodules adjusted for sex, age, tobacco and emphysema was associated with lung cancer with an OR 4.58, 95% CI (2.70 - 7.77) p <0.001. Conclusion: We found a greater percentage of women, tobacco consumption and prevalence of cancer in patients with non-solid lung nodules compared to the rest of patients.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA3026
Risk factors and prognosis of non-solid nodules in a lung cancer screening program
Objectives: To study the prevalence of non-solid lung nodules in patients undergoing lung cancer screening, analyze their prognosis during the follow-up and identify risk factors. Material and Methods: Investigations on non-solid lung nodules found on CT were revised. Medical records and database of the participants in a lung cancer screening program with low-dose chest CT (P-ELCAP (Pamplona – Early Lung Cancer Action Program) were analyzed. Tobacco, bronchiectasis, emphysema, age and sex data were compared between patients with and without non-solid nodules. The lung cancer frequency in both groups of patients was compared and the percentage of non-solid nodules that developed in cancer was determined. Results: We included 3624 patients. The prevalence of non-solid lung nodules was 7.51% and the prevalence of cancer among the patients was 2.24%. The progression into cancer from a non-solid nodule appear in 7 of 272 patients with non-solid nodules. In comparison with the rest of the patients, the group with non-solid lung nodules, its number of women was 94 (34.56%) vs. 927 (27.7%); p = 0.015 and the prevalence of lung cancer was 21 (7.72%) vs. 60 (1.79%) p <0.001. For the association of greater tobacco consumption, with the presence of non-solid nodules, adjusted for sex, an OR 1.01, 95% CI (1.00 - 1.01) p = 0.007 was obtained. The presence of non-solid nodules adjusted for sex, age, tobacco and emphysema was associated with lung cancer with an OR 4.58, 95% CI (2.70 - 7.77) p <0.001. Conclusion: We found a greater percentage of women, tobacco consumption and prevalence of cancer in patients with non-solid lung nodules compared to the rest of patients.